Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Menopause & Women's Health

CoverageMenopause & Women's Health

Does hormone therapy help depression or anxiety during perimenopause?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·10 studies analyzed·2 core studies·Applies to: perimenopausal and early postmenopausal women

Bottom line

Some trials suggest estrogen-based therapy may help depressive symptoms during the menopause transition, particularly when vasomotor symptoms coexist. It is not a substitute for standard treatment of major depressive disorder.[1–6]

Evidence confidence

Evidence Confidence

Moderate
LimitedModerateHigh

Relevant evidence exists, but study designs, populations, or conclusions differ enough to keep certainty moderate.

Key uncertainty. Patient selection and regimen effects vary across studies.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

Perimenopause depression HRT▼

Some trials suggest estrogen-based therapy may help depressive symptoms during the menopause transition, particularly when vasomotor symptoms coexist. It is not a substitute for standard treatment of major depressive disorder.

Menopause mood estrogen▼

Some trials suggest estrogen-based therapy may help depressive symptoms during the menopause transition, particularly when vasomotor symptoms coexist. It is not a substitute for standard treatment of major depressive disorder.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 10 relevant studies.

Overall finding

8 studies address vasomotor symptom associations, with weighted findings showing mixed findings. 2 studies address long-term cognitive decline / dementia, with weighted findings showing harm. 2 studies address venous thromboembolism, with weighted findings showing benefit. 2 studies address breast cancer, with weighted findings showing benefit. 4 randomized or systematic-review reports and 5 observational studies address treatment.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Mixed

Vasomotor symptom associations

moderate · 8 studies

8 studies address vasomotor symptom associations, with weighted findings showing mixed findings. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 29322164PMID 34513605PMID 41307293PMID 26838086PMID 38016166PMID 36749328PMID 40253593PMID 42606770
Harm signal

Long-term cognitive decline / dementia

moderate · 2 studies

2 studies address long-term cognitive decline / dementia, with weighted findings showing harm. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 34513605PMID 41307293
Favors treatment

Venous thromboembolism

moderate · 2 studies

2 studies address venous thromboembolism, with weighted findings showing benefit. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 36749328
Favors treatment

Breast cancer

moderate · 2 studies

2 studies address breast cancer, with weighted findings showing benefit. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 36749328
Mixed

Mood-related cognitive symptoms

moderate · 1 study

1 study addresses mood-related cognitive symptoms, with weighted findings showing mixed findings. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 29322164
Unclear

Mortality

moderate · 1 study

1 study addresses mortality, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293

Magnitude / clinical importance

Validated effect estimates in the analyzed set include RR 1.17; or 4. Statistical significance is not the same as clinical importance.

Where quantified, effects were often statistically detectable but small in absolute terms.

Agreement across studies

Most studies agree on vasomotor symptom associations (mixed findings), while long-term cognitive decline / dementia findings are harm and more consistent across domains.

Supports main conclusion: 5 · Neutral / mixed: 5 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • A severe impairment of cognitive function characterizes dementia.
  • Long-term follow-up of women using hormone therapy suggests that the risk profiles vary between combined hormone therapy and oestrogen-only therapy.
  • Brain fog, referring to menopause-related subjective cognitive difficulties, is common in midlife women.

Risks & harms

3 studies report safety-relevant findings. Design mix: Narrative review. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

Most studies included perimenopausal and early postmenopausal women.

What remains uncertain

  • Patient selection and regimen effects vary across studies.
  • Patient selection and regimen effects vary across studies.
  • Typical subjective cognitive complaints are not established as equivalent to dementia.

Clinical takeaway

Consider estrogen-based therapy for depressive symptoms during the menopause transition when vasomotor symptoms coexist, especially after standard psychiatric evaluation. HRT is adjunctive, not a substitute for treatment of major depressive disorder.

Mixed

Vasomotor symptom associations?

Mixed findings

moderate[29322164 · 34513605 · 41307293 · 26838086 · 38016166 · 36749328 · 40253593 · 42606770]

Harm signal

Long-term cognitive decline / dementia?

Harm

moderate[34513605 · 41307293]

Favors treatment

Venous thromboembolism?

Benefit

moderate[41307293 · 36749328]

Favors treatment

Breast cancer?

Benefit

moderate[41307293 · 36749328]

Mixed

Mood-related cognitive symptoms?

Mixed findings

moderate[29322164]

Unclear

Mortality?

Unclear findings

moderate[41307293]

Unclear

Fertility / spermatogenesis?

Unclear findings

moderate[41307293]

Unclear

Fractures?

Unclear findings

moderate[41307293]

4 randomized or systematic-review reports and 5 observational studies address treatment. Weighted treatment findings show mixed findings.

4 RCT / systematic review · 5 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

8 supporting studies add context beyond the core evidence base.

Regimen & duration

Differences in hormone type, dose, duration, and patient population affect how results should be interpreted.

Long-term uncertainty

Study quality or consistency across available evidence limits certainty.

10 analyzed studies

Strongest evidence

Supporting literature

Long-term hormone therapy for perimenopausal and postmenopausal women.

Hormone Therapy for Relieving Postmenopausal Vasomotor Symptoms: A Systematic Review.

Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.

+5 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Menopause & Women's Health.

Does hormone replacement therapy increase breast cancer risk?

Combined estrogen-progestin therapy is associated with a small increased breast cancer risk in WHI and observational data. Estrogen-alone in hysterectomized women showed lower risk in WHI, but interpretation depends on regimen, duration, and individual risk factors.

10 linked studies

Does hormone replacement therapy reduce cardiovascular risk in early menopause?

The timing hypothesis suggests earlier initiation may differ from late initiation, where WHI showed harm for combined therapy. Current guidelines emphasize individualized risk assessment rather than routine cardioprotection.

14 linked studies

Does hormone replacement therapy increase venous thromboembolism risk?

Oral estrogen increases venous thromboembolism risk compared with no therapy. Transdermal estrogen appears to carry lower thrombotic risk in observational studies and is often preferred in women at elevated VTE risk.

14 linked studies

Is there a critical timing window for cardiovascular benefit from HRT?

The critical-window concept proposes that starting HRT closer to menopause may yield different cardiovascular effects than starting later. WHI subgroup analyses inform but do not prove this hypothesis for routine practice.

14 linked studies

Go deeper on Menopause & Women's Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Menopause & Women's HealthView pricing